Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase

Yanti Octavia, Georgios Kararigas*, Martine de Boer, Ihsan Chrifi, Rinrada Kietadisorn, Melissa Swinnen, Hans Duimel, Fons K. Verheyen, Maarten M. Brandt, Daniela Fliegner, Caroline Cheng, Stefan Janssens, Dirk J. Duncker*, An L. Moens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

31 Citations (Web of Science)

Abstract

The use of doxorubicin (DOXO) as a chemotherapeutic drug has been hampered by cardiotoxicity leading to cardiomyopathy and heart failure. Folic acid (FA) is a modulator of endothelial nitric oxide (NO) synthase (eNOS), which in turn is an important player in diseases associated with NO insufficiency or NOS dysregulation, such as pressure overload and myocardial infarction. However, the role of FA in DOXO-induced cardiomyopathy is poorly understood. The aim of this study was to test the hypothesis that FA prevents DOXO-induced cardiomyopathy by modulating eNOS and mitochondrial structure and function. Male C57BL/6 mice were randomized to a single dose of DOXO (20mg/kg intraperitoneal) or sham. FA supplementation (10mg/day per oral) was started 7days before DOXO injection and continued thereafter. DOXO resulted in 70% mortality after 10days, with the surviving mice demonstrating a 30% reduction in stroke volume compared with sham groups. Pre-treatment with FA reduced mortality to 45% and improved stroke volume (both P

Original languageEnglish
Pages (from-to)3277-3287
Number of pages11
JournalJournal of Cellular and Molecular Medicine
Volume21
Issue number12
DOIs
Publication statusPublished - Dec 2017

Keywords

  • anthracycline
  • antioxidant enzyme
  • cardiotoxicity
  • free radical
  • nitric oxide
  • LEFT-VENTRICULAR DYSFUNCTION
  • CARDIAC DYSFUNCTION
  • CARDIOVASCULAR-DISEASE
  • INDUCED CARDIOTOXICITY
  • MITOCHONDRIAL-FUNCTION
  • PRESSURE-OVERLOAD
  • HEART-FAILURE
  • MORTALITY
  • PROTECTS
  • INJURY

Cite this